Physicians Physicians


banner overlay

KOELIS Trinity® for Prostate Fusion
Biopsy System Enhances Diagnosis and Care

Prostate cancer is among the top 10 cancer types globally, accounting for 7.3% of all cancer cases in 2020 according to the International Agency for Research on Cancer (IARC).1 Yet, the majority of prostate biopsies are still performed as random biopsies, despite new prostate cancer guidelines that recommend the early use of multiparametric magnetic resonance imaging (mpMRI) before a prostate biopsy in both biopsy naïve patients and in patients with a prior negative biopsy for the detection of prostate cancer.2

3D MRI/ultrasound fusion biopsy system

For over a decade KOELIS has assisted urologists and radiologists from around the world in their routine clinical practice, providing the latest technology for personalized prostate cancer care. The KOELIS Trinity® 3D MRI/ultrasound fusion biopsy system offers:

3D Imaging Software Automatically Compensates for Prostate and Patient Movement

KOELIS Trinity® delivers real-time 3D MRI/ultrasound fusion to improve prostate biopsy accuracy and cancer detection rates. The system employs our proprietary Organ-Based Tracking Fusion® (OBT) technology that tracks the prostate, not the probe. OBT automatically compensates for patient and prostate movement with no need for an additional technician to manually realign imagery. The result is exceptionally accurate fusion biopsy as precise as 2.5 mm.1

At KOELIS, we continue to innovate every day in collaboration with world-renowned universities and hospitals to offer physicians the latest advances in imaging that impact patient care and quality of life.


1. International Agency for Research on Cancer, 2020.

2. European Association of Urology, 2019.


Welcome to KOELIS®

Please choose a country or region.

  • US Site
  • International Site
trinity in action

See KOELIS Trinity® in Action

Request a live demo today